Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor^® in Ischemic Heart Failure and Label Extension for Ryoncil^® in Adults With GvHD

Mesoblast provided an update on continued momentum with US FDA regarding both accelerated approval pathway for Revascor^® in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation, and label extension for Ryoncil^® in adults with steroid refractory acute graft versus host disease.